Best Undervalued Stocks To Watch For 2019

By Parke Shall

We honestly wouldn’t be surprised if we saw somebody come in and make a bid for Mylan (NASDAQ:MYL) at this stage in the game.

We have written several articles talking about why we think the company is significantly undervalued, and now that some of the gray skies have cleared from in front of the company and it has settled with the Department of Justice, we believe it will be blue skies ahead for MYL. We wanted to take a second and talk about what we believe will be a very unique opportunity to own this company at a price significantly under fair market value.

Our last article on MYL talked about the opportunity to buy the company after it had settled with the Department of Justice over the classification of its EpiPen product. We made a prediction that the stock would eventually head back to $49 per share, which is where it was trading prior to the EpiPen scandal going mainstream. We also stated that the company could have about 75% upside over the course of the long term, a price target that we arrived at by putting a 12X multiple on recently reiterated $6 EPS estimates for 2018. With the stock now at $36, that upside potential moves to about 100%.

Best Undervalued Stocks To Watch For 2019: Surgery Partners, Inc.(SGRY)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Surgery Partners (SGRY)

    For more information about research offerings from Zacks Investment Research, visit

  • [By Max Byerly]

    Surgery Partners Inc (NASDAQ:SGRY) has been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $19.40.

  • [By Stephan Byrd]

    Tenet Healthcare (NYSE: THC) and Surgery Partners (NASDAQ:SGRY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.

  • [By Stephan Byrd]

    Surgery Partners (NASDAQ:SGRY) had its target price upped by stock analysts at Leerink Swann from $20.00 to $25.00 in a note issued to investors on Monday, The Fly reports. The brokerage currently has an “outperform” rating on the stock. Leerink Swann’s price objective points to a potential upside of 43.27% from the stock’s current price.

Best Undervalued Stocks To Watch For 2019: TRACON Pharmaceuticals, Inc.(TCON)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on TRACON Pharmaceuticals (TCON)

    For more information about research offerings from Zacks Investment Research, visit

Best Undervalued Stocks To Watch For 2019: Barnes & Noble, Inc.(BKS)

Advisors’ Opinion:

  • [By Paul Ausick]

    Barnes & Noble Inc. (NYSE: BKS) traded down nearly 17% Friday and posted a new 52-week low of $5.40 after closing Thursday at $6.50. The 52-week high is $11.80. Volume was about 5.4 million, more than 4 times the daily average of around 1.3 million shares. The company revealed that same-store sales tumbled 6.4% in November and December.

  • [By Douglas A. McIntyre]

    Barnes & Noble Inc. (NYSE: BKS) has received interest from potential buyers. The company’s board has decided to form a committee to look at offers in anticipation of the book retailer being sold. Even with legitimate offers that might place the company under new ownership, its core business is still dying.

  • [By Chris Hill]

    On this episode of Market Foolery, host Chris Hill and Motley Fool contributor Seth Jayson talk about some of the market’s biggest stories. Barnes & Noble (NYSE:BKS) popped some 20% after announcing it’s going up for sale — a premium that can’t possibly make the bookseller any more appealing to prospective buyers. Constellation Brands (NYSE:STZ) (NYSE:STZ-B) recently dipped its toe into the cannabis market through Canopy Growth (NYSE:CGC). Now it’s dipping its whole foot, upping its investment another $4 billion. Why doesn’t the company just focus on selling more alcohol? And with earnings season right around the corner, Seth shares what he’ll be watching in next week’s round of reports. Tune in to find out more.

  • [By Dan Caplinger]

    Thursday was a bad day on Wall Street, as major benchmarks fell sharply after worries about other financial markets took their toll on stocks. A substantial jump in bond yields has taken the 10-year Treasury to 3.2%, and some investors fear that higher rates could raise financing costs for companies, taking away some of their incentive to invest in further growth. However, even with the downward pressure on the overall market, some stocks had good showings. Barnes & Noble (NYSE:BKS), Paratek Pharmaceuticals (NASDAQ:PRTK), and Hortonworks (NASDAQ:HDP) were among the best performers on the day. Here’s why they did so well.

  • [By Chris Lange]

    Barnes & Noble Inc. (NYSE: BKS) has been the markets’ punching bag over the past couple of years, and things don’t seem to be changing anytime soon. The bookstore released its most recent quarterly results before the markets opened on Thursday, and this was met with investor trepidation.

  • [By Evan Niu, CFA]

    Shares of book retailer Barnes & Noble (NYSE:BKS) have surged today, up by 11% as of 12:37 p.m. EDT, after a prominent institutional investor disclosed a higher stake. Richard Schottenfeld’s Schottenfeld Opportunities Fund is pushing for a sale of the company.

Leave a Reply

Your email address will not be published. Required fields are marked *